The AdSS2 antibody targets adenylosuccinate synthase 2 (AdSS2), a key enzyme in the purine nucleotide cycle responsible for catalyzing the conversion of inosine monophosphate (IMP) and aspartate to adenylosuccinate. This mitochondrial enzyme plays a critical role in cellular energy metabolism, particularly in tissues with high energy demands, such as cardiac and skeletal muscle. Dysregulation of AdSS2 has been implicated in metabolic disorders, mitochondrial dysfunction, and certain cancers.
Research using AdSS2 antibodies has focused on elucidating its expression patterns and mechanistic contributions to disease. Studies suggest AdSS2 overexpression in hepatocellular carcinoma and colorectal cancer, where it may promote tumor progression by sustaining nucleotide synthesis and energy homeostasis. The antibody is widely employed in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels, subcellular localization, and interactions in both physiological and pathological contexts.
Recent investigations also explore AdSS2's potential as a therapeutic target, particularly in cancers reliant on purine metabolism. Inhibiting AdSS2 activity could disrupt nucleotide pools, impairing tumor growth. Additionally, its role in myocardial ischemia-reperfusion injury highlights relevance in cardiovascular research. The AdSS2 antibody thus serves as a vital tool for probing metabolic adaptations in disease, offering insights into diagnostic or therapeutic strategies targeting energy metabolism pathways.